Legal News

Commission approves mRNA vaccine for common respiratory virus

Published on: 23 August 2024
Published by LNB News

LNB News 23/08/2024

Document Information

Issue Date: 23 August 2024

Published Date: 23 August 2024

Jurisdiction(s): European Union

Article summary

The European Commission has authorised the mRNA vaccine ‘mResvia’ to protect adults over 60 against lower respiratory tract disease caused by respiratory syncytial virus (RSV) infection. This approval is the first vaccine to be authorised using mRNA technology to prevent a disease other than coronavirus (COVID-19). The European Medicines Agency authorisation comes ahead of the autumn/winter season when RSV infections tend to peak. National authorities will now decide on the vaccine’s use according to their vaccination plans.

Popular documents